Financial incentives in Japan increased biosimilar prescriptions in oncology, suggesting a model for promoting biosimilar use. Regulatory approvals in the US, Europe, and Japan could save over US$110 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results